Table 1.
Baseline characteristics and neurohumoral, hemodynamic, and functional status assessment before and after furosemide dose reduction among stable heart failure patients
| Reduced GFR (n=19) (<60 ml/min/1.73m2) | Preserved GFR (n=13) (≥60 ml/min/1.73m2) | |||
|---|---|---|---|---|
| Age, years | 76±2* | 68±3 | ||
| Female, n (percent) | 6 (32) | 4 (31) | ||
| Coronary artery disease, n (percent) | 12 (63) | 6 (46) | ||
| Diabetes mellitus, n (percent) | 4 (21) | 4 (31) | ||
| Hypertension, n (percent) | 10 (53) | 5 (38) | ||
| Hyperlipidemia, n (percent) | 12 (63) | 10 (77) | ||
| Ejection Fraction, n (percent) | 29±2 | 33±1 | ||
| Beta Blocker, n (percent) | 17 (89) | 13 (100) | ||
| ACEi/ARB, n (percent) | 13 (68) | 12 (92) | ||
| Aldosterone Antagonist, n (percent) | 5 (26) | 4 (31) | ||
| Nitrates/Hydralazine n (percent) | 7 (37) | 2 (15) | ||
| Baseline Dose Furosemide | Reduced Dose Furosemide | Baseline Dose Furosemide | Reduced Dose Furosemide | |
| Lasix Dose, mg per day | 119±14* | 66±9† | 102±13 | 57±8† |
| Weight, kilograms | 81±17 | 81±16 | 91±12 | 91±13 |
| Glomerular Filtration Rate (ml/min) | 42±3* | 50±4† | 77±3 | 73±5 |
| Plasma Renal Flow (ml/min) | 198±20 | 214±21 | 304±19 | 293±23 |
| Atrial Natriuretic Peptide | 233±48 | 291±60† | 168±44 | 163±34 |
| Plasma cGMP (pg/ml) | 5.7±0.8 | 7.0±1.0‡ | 5.0±0.9 | 4.6±0.7 |
| Plasma Renin Activity (ng/mL/hr) | 2.1±0.8 | 1.4±0.5 | 4.3±2.0 | 2.7±1.1 |
| Angiotensin II (pg/mL) | 3.1±0.7 | 3.2±0.9 | 3.3±0.6 | 3.4±1.0 |
| Aldosterone (ng/dL) | 4.9±0.6 | 4.9±0.6 | 7.9±1.8 | 7.6±1.3 |
| 6 Minute Walk (meters) | 327±20 | 336±23 | 428±30 | 419±32 |
| Minnesota Living with HF Score | 25±4 | 25±5 | 29±4 | 29±4 |
| Systolic Blood Pressure (mm Hg) | 117±5 | 121±5 | 114±4 | 114±4 |
| Diastolic Blood Pressure (mm Hg) | 67±2 | 68±2 | 70±2 | 70±3 |
| Heart Rate (beats per minute) | 67±2 | 66±2 | 66±3 | 68±4 |
Continuous variables compared using and paired (within group) t-test. Categorical variables compared using Chi-Square.
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; GFR, glomerular filtration rate; HF, heart failure
*
p<0.05 vs. Normal GFR, student’s t-test
†
p<0.05 vs. Baseline Dose Furosemide, paired t-test
‡
p=0.075 vs. Baseline Dose Furosemide, paired t-test